Description
Sian will be presenting real world data gathered form the European Field trial study detailing clinical efficacy and safety of the single-administration of fluralaner injectable suspension (Bravecto injectable©) to dogs for flea and tick control over one year. This as yet (Oct 24) unpublished paper includes insights into the breeds and ages of the participating dogs, as well as the concurrent medications prescribed to them, both long term and short-course. Both healthy dogs and those with skin lesions suspicious of FAD were included in the trial, and a discussion of the suspected Adverse Events reported during the trial period will form part of this presentation. Questions will be welcome.
Learning Objectives
- To understand the mode of action of Bravecto Injectable and how it can provide 12 months of protection
- To gain confidence in the safety of this longer-acting addition to the Bravecto portfolio,
- To gain confidence in the efficacy of Bravecto Injectable in the face of emerging parasite threats
- To confidently prescribe Bravecto Injectable where appropriate
- To be confident to prescribe Bravecto Injectable alongside commonly used drugs in a general population of dogs
